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TNFa b s t r a c t
During the quarter of a century since TNF was isolated, much knowledge has been gained of the identity
of other ligands besides TNF in the TNF cytokine family, and of the proximal signaling molecules that
these ligands activate. The numerous laboratories contributing to this advance have approached TNF
research from various points of view. The research pathway taken in my own laboratory, which is out-
lined in this article, has been driven by the desire to elucidate mechanisms that regulate cell death.
 2013 The Author. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
When a student in my laboratory reaches a new ﬁnding, I make
sure to point out that ﬁndings happen when the time for them is
ripe, and therefore that some workers somewhere else in the world
might at this very moment be at the point of making the same dis-
covery. I am continually astonished by the frequent corroboration
of this warning. In the study of TNF, as in practically all ﬁelds of
human achievement, there is hardly any important ﬁnding that
can be credited to only one individual or a single laboratory. Most
of the major discoveries can be traced to a series of prior revela-
tions, and most have been reached in parallel to similar ﬁndings
that lagged only slightly in the race to be ‘‘ﬁrst to publish’’. Still,
even when the conclusions are identical, each of the laboratories
has contributed a different point of view of these conclusions, de-
ﬁned by the different basic question that motivated that particular
laboratory.
For this article I was asked to describe the line of thoughts that
directed the studies of the TNF family in my laboratory. In doing so,
I will try to keep reminding readers of the contributions by others
to the advances mentioned here. Owing to length limitations, how-
ever, it was not possible for me to assign proper credit to those
contributions, or to list the individual researchers in my own lab-
oratory who took part in our work, and for that I apologize. Being
likewise unable to provide a complete account of the literature, I
have simply listed some of the publications by my own group,along with a few other seminal works that relate to the original
discovery of TNF.
2. In transition from B.C. to A.C
I was lucky enough to be involved in the study of TNF before it
was isolated, and could therefore experience the elation that
comes when a complicated set of descriptive data monitored by
using a crude compound is suddenly illuminated through the use
of the pure molecule. In the shift from the ‘‘B.C.’’ (before cloning)
to the ‘‘A.C.’’ (after cloning) era, the change was not only in the abil-
ity to better explore the functions of TNF, but also in validation of
the belief in the mere existence of such functions. When TNF was
isolated, Lloyd Old remarked ‘‘It has been cloned, therefore it ex-
ists!’’—a quip which, for all those who were attempting to study
this protein prior to its puriﬁcation, expressed the frustration expe-
rienced in studying a compound whose very existence seemed in
doubt [1]. Some of my colleagues at that time used to say, only half
in jest, that this ‘‘TNF’’ that I was claiming to study was actually
nothing but ‘‘tinef’’ (a Yiddish term meaning dirt). Given the doubt
about its existence, not many scientists were studying TNF. More-
over, as happened also with other pleiotropic cytokines, the differ-
ent laboratories exploring it approached the work by addressing
distinct questions and did not realize that they were studying
the functions of the same protein. Even when the question ad-
dressed was the same, there were those who were unaware that
other scientists were also asking it.
A number of distinct pathways of research contributed to the ini-
tial awareness that TNF exists. At the end of the 19th century, the re-
ported successofWilliamColey in applyingbacterial extracts to cure
cancer patients by triggering acute inﬂammation sparked a line of
research in which such curative effects were induced in mouse
models of cancer. This was ﬁrst done by injecting mice with crude
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endotoxin, and then, as ﬁrst reported by the group of LloydOld, with
amammalian cell-derived compound that was induced by bacterial
compounds and which they dubbed ‘‘tumor necrosis factor’’ (TNF)
[1]. Signiﬁcantly before the last ﬁnding (already in the 1940s), Valy
Menkin, in exploring the role of cell-derived soluble mediators in
various aspects of inﬂammation, suggested that tissue damage
resulting from inﬂammation is also mediated by a dedicated cell-
derived factor, which Menkin dubbed ‘‘necrosin’’ [2]. Gale Granger
in exploring the mechanism of T cell-mediated cytotoxicity [3],
and Nancy Ruddle and ByronWaxman in studying the mechanisms
of delayed type hypersensitivity [4], found that lymphocytes secrete
protein(s)with cytotoxic activity, andnamed them ‘‘lymphotoxins’’.
Anthony Cerami and Bruce Beutler discerned what was later called
TNF by tracing catabolic effects of macrophage-derived cytokines,
and accordingly dubbed it ‘‘cachectin’’ [5].
The ﬁndings that led me to the study of TNF were reached ser-
endipitously, via exploration of a subject that is now highly popu-
lar but at that time was addressed in only a few laboratories,
namely the mechanisms of cell death. What drove scientists to
start studying cell death was the emerging belief that it involves
speciﬁc predestined mechanisms. Today this conviction is based
on actual knowledge of such mechanisms. When I began studying
TNF there was no such knowledge, although there were already
several other indications that death can occur in a programmed
manner. For me, the most compelling of those signs came from
studies suggesting that the vulnerability of cells to death could
be modulated by biological factors. The notion that death could
be regulated seemed to implicate predestined mechanisms, and I
decided to study this regulation.
Probably because I was introduced to theworld of science in lab-
oratories where the focus was on hormone-induced signaling—ﬁrst
withMichael Schramm and Zvi Seliger, who pioneered signaling re-
search in Israel, and thenwith Ira Pastan at the NIH—I decided to try
exploring cell death through the study of molecular signaling. With
this purpose in mind, I searched for an extracellular ‘‘hormone’’
capable of controlling cell viability, with the idea that such a ‘‘death
hormone’’, if found, could be used as a molecular probe to explore
details of the intracellular molecular events affecting cell death.
It was already well known that one of the ways in which the
interferons (IFNs) contribute to immune defense is by facilitating
destruction of tumor cells and cells infected with microbes. IFNs
had been shown to alter the vulnerability of cells to immune-medi-
ated killing, as well as to foster the cell-killing activities of killer leu-
kocytes. I decided to explore themechanismsbywhich the ‘‘immune
interferon’’, (IFN)-c, which at that time had not yet been isolated, af-
fects cell death. I began by exploring, in collaboration with Michel
Revel and Marc Fellous, the effects of IFNs on cell vulnerability to
death. Althoughwewere able to report some ﬁndings of great inter-
est about how natural killer cells recognize their target cells [6,7],
and the mechanisms of action and cellular functions of IFN-c [8],
those studies from my point of view rapidly reached a dead end. I
could see no way to advance towards molecular understanding of
cell-death regulation without ﬁrst identifying a molecule with a
more intimate relationship to the death process itself.
By that time it had already been determined that the various ef-
fects of IFNare allmediatedby speciﬁc IFN-inducedproteins. I there-
fore decided to embark on an attempt to discover an IFN-induced
‘‘death protein’’ that could account for the enhanced cell-killing
activities displayed by various leukocytes after IFN treatment. This
ledmygroup to theﬁnding that some leukocytes,when treatedwith
IFN, produce and secrete factor(s) with cell-killing activity [9].
What was particularly exciting about this interferon-induced
‘‘cytotoxin’’, as we called it, was that it did not seem to act merely
as a toxic compound but rather as an agent that instruct cells to
commit suicide, and that it did this in a context-dependent man-ner. Whereas some other programmed cell-death processes known
at that time were shown to depend on the synthesis of new cellular
proteins (and such dependence was even considered by some sci-
entists as deﬁnitive for the ‘‘programmed’’ nature of a cell-death
process), the cell-killing ability of our ‘‘cytotoxin’’ was independent
of protein synthesis. When protein synthesis was blocked, not only
was the killing not arrested but it was dramatically enhanced.
Moreover, with certain types of cells, when protein synthesis was
not blocked this ‘‘cytotoxin’’ not only failed to trigger death, but
on the contrary, induced in these cells resistance to their own cyto-
toxicity (as assessed by reapplication of the ‘‘cytotoxin’’ to the
same cells, this time in the presence of a protein-synthesis block-
er). Chromatographic analysis suggested that the proteins inducing
this resistance to death corresponded in part to the same protein
that induced death [10], and in part to another cytokine, which
we later identiﬁed as interleukin (IL)-1b [11,12].
To further clarify the relationship between these two opposing
activities—induction of cell death and resistance to death—we had
to purify the protein(s) that mediate them. The amounts of leuko-
cytes required for this purpose were far greater than could be han-
dled by a small laboratory in an Israeli academic institute, and we
therefore had to devise a more sophisticated approach. We immu-
nized mice with impure preparations of the protein and then used
their spleens to obtain monoclonal antibodies that were then
applied to isolate the protein [13]. While we were struggling to
isolate our ‘‘cytotoxin’’, Bharat Aggarwal’s group reported the
isolation of a leukocyte-derived cyototoxic protein. According to
a number of its reported features, however, we could tell that this
protein was not our ‘‘cytotoxin’’. About six months after we had
ﬁnally managed to obtain the monoclonal antibody against ‘‘cyto-
toxin’’, the cloning of another cytotoxic protein was reported from
the laboratory of David Goeddel, and shortly afterwards also from
the laboratories of Walter Fiers and several others. This one was
clearly identical with the protein we had isolated. After some hes-
itations and arguments over nomenclature, the cytotoxic protein to
whose isolation we had contributed was called ‘‘tumor necrosis
factor’’ (TNF), while the cytotoxic protein isolated by Aggarwal
somewhat earlier was dubbed ‘lymphotoxin-a’ (LTa).
On examining the cellular activity of the puriﬁed cytotoxin/TNF,
we found that it could induce both cell death and resistance to cell
death under the test conditions described above [13]. This ﬁnding
made it clear that the protein was not merely a toxic molecule but
rather a regulator of several different cell functions. Nevertheless,
in papers published over several years afterwards it was still sug-
gested that TNF does possess some intrinsic cell-killing activity
(mediated by its proposed ability to be inserted into lipid bilayers
and act there as a pore-forming molecule). It took ﬁve more years
to win general recognition that TNF is a cytokine, i.e., a protein that
affects cells via receptor-mediated signaling. Thiswasunequivocally
veriﬁedby isolating theTNF receptors and showing that triggeringof
those receptors via their cross-linkingwith anti-receptor antibodies
sufﬁced to induce cell death (aswell as a variety of other, nondeadly,
functional changes), even in the absence of TNF [14].
For us, the most exciting outcome at that time was the knowl-
edge that we now possessed a genuine regulator of cell viability.
We believed that we had arrived at the Archimedean point of
leverage for analysis of the cell-death mechanisms that we had
been seeking.3. Isolating soluble forms of the TNF receptors: an unexpected
gain from simultaneous exploration of molecular mechanisms
and therapeutic potential
The isolation of TNF and LTa resulted in a vast increase in
knowledge of the functions of these two cytokines. From being a
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they were transformed within a very short time into an object of
enthusiastic exploration in numerous laboratories. A scientiﬁc con-
gress devoted to the function of these cytokines that was held in
Heidelberg in 1987, just two years after they were isolated and
cloned, attracted close to 500 excited participants who presented
more than 200 abstracts covering a wide range of assorted subjects
of research pertaining to TNF functions. As more knowledge accu-
mulated and more members of the TNF ligand family were discov-
ered, the number of scientists exploring the ﬁeld multiplied. The
Heidelberg meeting was followed two years later by another one,
and since then the International TNF Conference has been a bien-
nial event, the latest of which was the 14th in the series.
The proliferation in knowledge of cellular functions of TNF in
the early years after its cloning focused attention on its mecha-
nisms of action. Studies from several laboratories rapidly clariﬁed
that TNF binds to speciﬁc cell-surface receptor(s) and that those
also serve as the receptor(s) for LTa (e.g. [15]). However, because
of their extremely low levels of expression, several years went by
before these receptors were successfully isolated.
During that time, burgeoning knowledge on the diverse in-vivo
consequences of TNF function pointed to an important causal role
for TNF in the pathology of various chronic and acute inﬂammatory
disorders. In my laboratory, therefore, along with our efforts to iso-
late the TNF receptors—which seemed crucial for gaining further
knowledge of the mechanisms of cell-death regulation by TNF—
we also sought to understand mechanisms affecting the patholog-
ical effects of TNF in vivo, in the hope of deducing new approaches
to therapy.
Unexpectedly, these two lines of research came to merge. On
the assumption that nature would not have allowed itself to gener-
ate a cytokine having deleterious effects without generating an
accompanying counteractant, we explored the possibility that cells
also secrete one or more antagonists to TNF. We ﬁrst thought of
searching for such inhibitors in blisters or sera of people with dis-
eases that seemed to involve TNF, but eventually chose to examine
their urine, which was much easier to obtain in large amounts. Our
studies in vitro showed that the proteins found in urine samples
from affected patients indeed inhibited the cell-killing activity of
TNF, and that they did so by binding TNF and thus blocking its
binding to cells. Urine of healthy subjects demonstrated the same
activity, though less strongly than the urine of febrile patients. We
embarked on purifying the ‘‘urinary TNF-binding-proteins’’, ini-
tially from urine collected at the lavatories in our department at
the Weizmann Institute, and then from samples of concentrated
urinary proteins obtained from Ares Serono Inc. Using chromato-
graphic approaches we were able to isolate a TNF-binding protein
with inhibitory activity against TNF, and then two years later by
using TNF afﬁnity columns, a second one. Sequencing and cloning
of these two TNF inhibitors and studying the regulation of their
expression revealed that they corresponded to the extracellular do-
mains of two cell-surface TNF receptors [16–18].
As mentioned above, important advances are often reached at
about the same time by different laboratories. This was also the
case with regard to the search for TNF receptors. Not long after
we reported the isolation and sequencing of the soluble TNF recep-
tors, soluble and membrane-bound forms of these receptors were
found to have been isolated and cloned independently by several
other groups, including those of Inge Olsson, Phillippe Seckinger
and Jean-Michel Dayer, Werner Lesslauer, David Goeddel and Craig
Smith. Each laboratory approached the isolation of TNF receptors
from a different starting point, allowing each group to make a dis-
tinct contribution to knowledge of the function of these receptors.
In our case, discovery of the receptors in soluble form focused
attention on their potential therapeutic use. Subsequently, both
of these soluble receptors were indeed applied therapeutically,the soluble form of the p75 TNF receptor (TNF receptor superfamily
member 1B; TNFRSF1B) as a fusion protein with the Fc portion of
immunoglobulin (Enbrel, etanercept), and the soluble p55 recep-
tor (TNFRSF1A) in its natural form (onercept), which has shown
impressive therapeutic effects in clinical trials but has not yet
reached the market.
This discovery of the soluble TNF receptors also directed atten-
tion to the mechanisms of receptor shedding and pointed to the
utility of urinary protein concentrates as a source of crude material
for the isolation of shed and secreted forms of other receptors. Such
crude preparations of urinary proteins were indeed later applied to
isolate several additional receptors, including those of IL-6, IFN-c,
IL-18 and IFN-a/b.4. Exploring the signaling mechanisms for cell death, for
resistance to death, and for regulation of immune functions by
receptors of the TNF family
Isolation of the membrane-associated and the soluble forms of
the TNF receptors provided the means of advancing towards clari-
ﬁcation of the receptors’ signaling mechanisms for cell death and
various other changes. Importantly, it led to the identiﬁcation of
the so-called ‘‘extrinsic cell death pathway’’ which, together with
knowledge of the ‘‘intrinsic cell death pathway’’ gained at about
the same period, laid the groundwork for our current perception
of how apoptotic cell death is controlled. It also contributed pivot-
ally to our knowledge of how transcription factors of the NF-jB
family are activated.
In the ﬁrst steps of these analyses, our exploration of the mech-
anistic relationship between the shedding of the TNF receptors and
their signaling activities pointed to the existence of distinct struc-
tural motifs in the receptors, including a region within their intra-
cellular domain that mediates induction of death [19,20]. Studies
by Shige Nagata and David Goeddel revealed structural homology
between this region—the ‘‘death domain’’—and a death-inducing
region in Fas (another receptor of the TNF family identiﬁed and
cloned by Shin Yonehara, Peter Krammer and Shige Nagata).
By that time it had become clear that, as in the case of some
other programmed death processes, the apoptotic cell death
induced by TNF is exerted through the activation of caspases, a
family of proteases expressed constitutively in practically all cells.
Studies from David Baltimore’s laboratory were the ﬁrst to indicate
that induction of resistance to TNF-induced death by agents such
as TNF itself and IL-1, which unlike death induction by TNF does
depend on protein synthesis, is largely mediated by activation of
transcription factors of the NF-jB family (an activation that is ini-
tiated by phosphorylation of the inhibitory IjB proteins). Cloning
of the TNF receptors and the subsequent cloning of Fas by Shige
Nagata and Peter Krammer provided the modus operandi for
sequential analysis of the series of protein interactions leading
from these receptors to caspase activation and IjB
phosphorylation.
Two-hybrid screening and proteomic analyses in our laboratory
and in the laboratories of Peter Krammer, Vishva Dixit, and Dave
Goeddel revealed that the death domain is a protein-binding motif
that self-associates [21] and also binds to death domains in other
proteins. These investigations led, moreover, to identiﬁcation of
the death domain-containing adapter proteins FADD (or, as we
called it, MORT1 [22]) and TRADD. In addition, they led to the dis-
covery of caspase-8 (or, as we called it, MACH [23]) and caspase-
10, the proximal death-inducing enzymes that associate with
FADD/MORT1 through a motif related to the death domain. This
motif was later called ‘death-effector domain’. Activation of
caspase-8 and caspase-10 upon receptor triggering was found to
result in the processing and thus the activation of other caspases
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proteins and hence initiation of the apoptotic cell-death program.
Elucidation of the NF-jB activation pathways proceeded in sim-
ilar piggyback fashion, with identiﬁcation of one of the proteins
serving as the basis for screening for others that bind to it. In
searching for proteins that associate with the p75 TNF receptor,
David Goeddel’s group discovered the TRAF adapter family and
the ubiquitin ligases cIAP1 and cIAP2. Later on, several additional
members of the TRAF family were discovered by other research
groups. Those proteins, as well as the protein kinase RIPK1 that
was discovered by Brian Seed in a two-hybrid screen with the
death domain of Fas, could be shown to cooperate in initiating sig-
naling for NF-jB activation. Our knowledge of how they do so was
obtained from routes that were traced both downstream (from
these receptor-associated proteins) and upstream (from the NF-
jB proteins themselves) and met halfway. By screening for pro-
teins that bind to TRAF2 we identiﬁed an NF-jB-activating protein
kinase that we called NIK [24]. David Goeddel’s group then showed
that NIK binds to a protein, now called IKKa, which is capable of
phosphorylating IjB. At about the same time several groups,
including that of Michael Karin, managed to isolate the signaling
complex that phosphorylates IjB and found that it contains both
IKKa and a related protein kinase, IKKb. In addition, this complex
was found to contain an adapter protein, which Alain Israel called
NEMO and Michael Karin called IKKc. When the identiﬁcation of
NEMO/IKKc was ﬁrst reported, we were puzzled because this pro-
tein had popped up earlier in our two-hybrid screening for proteins
that bind to RIPK1 and affect NF-jB activation. On further charac-
terization, we conﬁrmed that NEMO indeed binds to RIPK1 upon
TNF treatment while maintaining its association with IKKa and
IKKb, and is thus recruited together with these kinases to the
TNF receptor with which RIPK1 associates. We also found that this
recruitment of IKKa and IKKb along with NEMO to the TNF recep-
tor is a crucial step in the receptor’s initiation of NF-jB activation
[25]. This so-called ‘‘canonical’’ pathway for NF-jB activation leads
to phosphorylation of IjB by IKKb and hence to activation of NF-jB
complexes that IjB blocks, such as the p65/p50 NF-jB dimer. Acti-
vation of the canonical NF-jB pathway by TNF plays a major role in
its proinﬂammatory effects. On the other hand, activation of IKKa
by NIK was found to occur independently of NEMO and to lead,
through the ‘‘alternative NF-jB pathway’’, to generation of a dis-
tinct active NF-jB dimer, RelB/p52. NIK also activates the canonical
pathway, but only in response to certain receptors of the TNF fam-
ily other than TNF itself (e.g., CD40, BR3, CD27) that also activate
the alternative NF-jB pathway, and employ both pathways to con-
trol cellular functions that contribute to the regulation of adaptive
immunity [26].
Subsequent work, in which our laboratory collaborated with
that of Alain Israel, led to identiﬁcation of CYLD, a NEMO-binding
protein that blocks TNF-mediated signaling by virtue of its deubiq-
uitination activity directed speciﬁcally against K63-linked poly-
ubiquitin chains [27]. We found that NEMO also binds to a
TNF-induced inhibitor of TNF signaling called A20 [25], which
was discovered much earlier by Vishva Dixit and later was also
found by him to possess deubiquitination activity. Findings by
James Chen and others clariﬁed that linkage of polyubiquitin
chains to RIPK1 and to other receptor-associated signaling proteins
is required for the initiation of NF-jB activation by TNF and by
some other receptors, and that this accounts for the ability of
deubiquitinases like CYLD and A20 to block NF-jB activation once
they are recruited in association with NEMO to the TNF receptor.
Although many details are still missing, the basic mechanisms
underlying the ability of ligands of the TNF family to induce both
apoptotic cell death and resistance to it now seem clear. Apoptosis
is induced through sequential activation of caspases, starting with
the recruitment of caspase-8 and caspase-10 to the receptor-induced signaling complexes, and since the caspases are constitu-
tively present in cells, death induction occurs in a protein-synthe-
sis independent manner. On the other hand, induction of resistance
to death by TNF requires activation of transcription factors such as
NF-jB. This activation is initiated by triggering the function of a
series of adapter proteins and enzymes—ubiquitin ligases and pro-
tein kinases—that also pre-exist in the cell. However, to impose
resistance to death, such triggering must yield enhanced synthesis
of some new proteins. cFLIP, an enzymatically inactive protein that
resembles caspase-8 and was discovered by several laboratories
including ours [28] and that of Jurg Tschopp, is one of those in-
duced proteins that blocks death induction. It does so by interfer-
ence with the activation of caspase-8.5. Expanding our knowledge further
The isolation and cloning of TNF jumpstarted an era of gene
hunting during which, over almost a quarter of century, novel
members of the TNF family have been cloned and the protein–pro-
tein interactions and enzymatic activations sparked by binding of
these ligands to their receptors have been tracked. Altogether,
these ﬁndings have yielded a detailed picture of the signaling path-
ways initiated by the TNF family ligands.
However, alongside this explosive increase in the number of
known molecules, our knowledge of their biological functions
has also broadened. Numerous immune functions that are regu-
lated by members of the TNF family are currently known. Some
of these ligands also play important roles in embryonic develop-
ment. We now face a major question: how does the rather limited
set of signaling molecules found to act downstream of the TNF
family account for such a wide range of regulatory functions?
As in other areas of biological research, the importance of pro-
gressing towards better understanding of the TNF story transcends
the mere need to satisfy our scientiﬁc curiosity. Better understand-
ing is required so that we can more effectively apply our knowl-
edge of the function of the TNF family to therapy. Studies
pioneered by Anthony Cerami, Marc Feldmann, Ravinder Maini,
Sander van Deventer and others have revealed the immense ther-
apeutic potential for modulation of TNF family-induced signaling
in disease. Millions of patients have already derived beneﬁt from
such therapies. Nevertheless, our current level of understanding
of the functions of these ligands and their mechanisms does not
yet allow us to deﬁne the mechanistic basis for the therapeutic ef-
fects with sufﬁcient precision. We cannot yet tell which of the dis-
eases involving TNF family members can gain from such therapy,
which particular patients are likely to beneﬁt and which are not,
and what must be done to increase the proportion of responders.
After caspase-8 was cloned and was shown to initiate the
induction of apoptotic cell death by receptors of the TNF family,
some of my students wondered whether any further work on this
enzyme was worth doing. Shouldn’t we now shift, they asked me,
to new questions and new molecules? My answer was that since
the main function of the signaling machinery activated by the
TNF family is to control immune defense, and since immune de-
fense has been evolving over millions of years of host–pathogen
combat, I could not believe that we had reached the stage where
we knew all there was to know about this protein, given its appar-
ently central role in such signaling.
Over the 17 years that have passed since the caspase-8 story
took off, functional studies of the various proximal TNF-regulated
signaling proteins have indeed conﬁrmed that there is much more
to them than initially met the eye. In the case of capsase-8, induc-
tion of apoptotic cell death turned out to be just one of a variety of
cellular functions to which this enzyme contributes [29–31]. A
common denominator in several of these functions is that they
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different ways. Apoptotic cell death itself contributes to suppres-
sion of innate immunity by affecting cell-surface determinants of
the dead cells. Conversely, necrotic cell death, which—as originally
found by Linda Gooding—can also be induced by TNF, results in the
release of cellular components that may trigger inﬂammation. As
emerged from the laboratory of Peter Vandenabeele, caspase-8,
while mediating induction of apoptotic cell death, also serves an
opposite, inhibitory role in the regulation of necrotic cell death.
Several other mechanisms triggering innate immune functions
are also blocked by caspase-8 through its direct effects on the sig-
naling complexes initiating them [32–34].
Thus, like the cytokines themselves, the signaling molecules
activated by them are not necessarily monofunctional, and can
be found rather to serve, depending on the context, a number of
different roles.
The late Arthur Kornberg used to describe the history of biolog-
ical research as a series of hunting periods. Thus, in the context of
cytokine research, the initial B.C. era of ‘‘cytokine-function hunt-
ers’’, in which clues for various cytokine-mediated activities were
obtained by detecting distinct functional effects of crude leukocyte-
secreted proteins, was followed by the era of ‘‘hardware hunting’’,
in which ligands, receptors and signaling proteins were cloned.
Paraphrasing Kornberg, we have now entered the ‘‘software-
hunter’’ era (Kornberg would perhaps have called us headhunters,
a term that he used to apply in another sense), where we seek to
understand the operative instructions executed by of Nature in
applying such a limited set of signaling molecules to coordinate
and control the multifaceted function of our immune defense
system.
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